University of Pennsylvania study demonstrates [18F]FTT is a biomarker of ovarian cancer response to PARP Inhibitor Treatment

University of Pennsylvania publishes study of efficacy of [211At]PTT  demonstrating complete tumor response in 81.8% of high-risk neuroblastoma tumors in mice with tolerable hematologic and marrow toxicity.

Partner with us

Learn how you can be a part of the paradigm-changing solution that will change the way we treat cancer.